Get started

Chinook Therapeutics (United States)

Homepage: chinooktx.com
Alternate name: Chinook Therapeutics, Inc.
ROR: 00xbahf74
OpenAlex ID: I4405270553
Atrasentan in Patients with IgA Nephropathy
2024 · Hiddo J.L. Heerspink, Meg Jardine, et al. · New England Journal of Medicine · 149
Defining cellular complexity in human autosomal dominant polycystic kidney disease by multimodal single cell analysis
2022 · Yoshiharu Muto, Eryn E. Dixon, et al. · Nature Communications · 123
PDF
Targeting the Endothelin A Receptor in IgA Nephropathy
2023 · Donald E. Kohan, Jonathan Barratt, et al. · Kidney International Reports · 60
PDF
Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
2023 · Matthew C. Baker, Khushboo Sheth, et al. · JAMA Network Open · 54
PDF
Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy
2025 · Laura Kooienga, Jeannette Lo, et al. · Kidney International · 47
PDF
Increased risk of osteoarthritis in patients with atopic disease
2023 · Matthew C Baker, Khushboo Sheth, et al. · Annals of the Rheumatic Diseases · 37
PDF
Dual Glycolate Oxidase/Lactate Dehydrogenase A Inhibitors for Primary Hyperoxaluria
2021 · Jinyue Ding, Rajesh Gumpena, et al. · ACS Medicinal Chemistry Letters · 23
Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
2024 · Hiddo J.L. Heerspink, Meg Jardine, et al. · Kidney International Reports · 22
PDF
POS-109 INTERIM RESULTS OF PHASE 1 AND 2 TRIALS TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND CLINICAL ACTIVITY OF BION-1301 IN PATIENTS WITH IgA NEPHROPATHY
2022 · J. Barratt, B. Hour, et al. · Kidney International Reports · 15
Patients With Immunoglobulin A Nephropathy Show Abnormal Frequencies of B Cell Subsets, Unconventional T Cells, and High Levels of Galactose-Deficient IgA1–Coated Gut Bacteria
2024 · Micaela Gentile, Nina Goerlich, et al. · Kidney International Reports · 14
PDF
Fc 040interim Results of Phase 1 and 2 Trials to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Bion-1301 in Patients With Iga Nephropathy
2021 · Jonathan Barratt, Billy Hour, et al. · Nephrology Dialysis Transplantation · 14
Population pharmacokinetics of zanidatamab, an anti-HER2 biparatopic antibody, in patients with advanced or metastatic cancer
2022 · Jeffrey R. Proctor, Elaina M. Gartner, et al. · Cancer Chemotherapy and Pharmacology · 13
Wcn23-1126 Atrasentan for the Treatment of Iga Nephropathy: Interim Results of the Affinity Study
2023 · S.G. Kim, L.A. Inker, et al. · Kidney International Reports · 12
PDF
FC052: Atrasentan for the Treatment of IGA Nephropathy: Interim Results from the Affinity Study
2022 · Sung-Gyun Kim, Nam Vo, et al. · Nephrology Dialysis Transplantation · 11
Remote Delivery of the Chronic Pain Self-management Program Using Self-directed Materials and Small-group Telephone Support: A Pilot Study
2021 · Khushboo Sheth, Philip L. Ritter, et al. · Journal of Applied Gerontology · 10
Wcn24-1837 Beyond: a Phase 3, Randomized, Double-blind, Placebocontrolled Trial of Zigakibart in Adults With Iga Nephropathy
2024 · Hernán Trimarchi, Jonathan Barratt, et al. · Kidney International Reports · 8
MO212: Updated Interim Results of A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Activity of BION-1301 in Patients With IGA Nephropathy
2022 · Jonathan Barratt, Laura Kooienga, et al. · Nephrology Dialysis Transplantation · 8
#4337 Updated Interim Results of a Phase 1/2 Study of Bion-1301 in Patients With Iga Nephropathy
2023 · Jonathan Barratt, Laura Kooienga, et al. · Nephrology Dialysis Transplantation · 7
PDF
Characterization of CHK-336, A First-in-Class, Liver-Targeted, Small-Molecule Lactate Dehydrogenase Inhibitor for Hyperoxaluria Treatment
2025 · Jennifer H. Cox, Marc-Olivier Boily, et al. · Journal of the American Society of Nephrology · 6
WCN23-1107 A PHASE 1/2 MULTICENTER STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIS OF BION-1301 IN HEALTHY VOLUNTEERS AND ADULTS WITH IgA NEPHROPATHY
2023 · S.G. Kim, E.Y. Lee, et al. · Kidney International Reports · 6
PDF
WCN25-1585 A Phase 1/2 Trial of Zigakibart in IgA Nephropathy (IgAN)
2025 · Jonathan Barratt, Biruh Workeneh, et al. · Kidney International Reports · 5
PDF
Model‐Informed Approach to Recommend Burosumab Dosing Regimens for Pediatric and Adult Patients With the Ultrarare Disease Tumor‐Induced Osteomalacia
2024 · Matthew W. Hruska, Lamia Sid‐Otmane, et al. · Clinical Pharmacology & Therapeutics · 4
PDF
A practical guide to the appropriate analysis of eGFR data over time: A simulation study
2024 · Todd DeVries, Kevin J. Carroll, et al. · Pharmaceutical Statistics · 4
PDF
#4341 Assist Study Design: a Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Patients With Iga Nephropathy (igan) on Sglt2i
2023 · Hiddo Lambers Heerspink, Jonathan Barratt, et al. · Nephrology Dialysis Transplantation · 4
PDF
POS-527 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Atrasentan in Patients with IgA Nephropathy (The ALIGN Study)
2022 · H. Lambers Heerspink, M. Jardine, et al. · Kidney International Reports · 4
Works count: 65
Citation count: 2,344
Year
Topic
Type